Hauptseite > Publikationsdatenbank > Prediction of radiation-induced toxicity by in vitro radiosensitivity of lymphocytes in prostate cancer patients > print

001     808538
005     20210129222808.0
024 7 _ |a 10.2217/fon.15.334
|2 doi
024 7 _ |a 1479-6694
|2 ISSN
024 7 _ |a 1744-8301
|2 ISSN
024 7 _ |a WOS:000370695600008
|2 WOS
037 _ _ |a FZJ-2016-02276
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Pinkawa, Michael
|0 P:(DE-HGF)0
|b 0
|e Corresponding author
245 _ _ |a Prediction of radiation-induced toxicity by in vitro radiosensitivity of lymphocytes in prostate cancer patients
260 _ _ |a London
|c 2016
|b Future Medicine Ltd
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1506327376_17752
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Aim: To identify predictive assays for radiation-induced toxicity in prostate cancer patients.Patients & methods: Patients have been surveyed prospectively before and up to 16 monthsafter radiotherapy using a validated questionnaire. Subgroups of 25 patients with minorand larger score changes, respectively, were selected for γ-H2AX, G2 and Annexin V assays.Results: A significantly higher spontaneous chromatid aberration yield (HR: 1.46 [95% CI:1.02–2.09]; p = 0.04), higher levels of early apoptotic (HR: 1.12 [95% CI: 1.01–1.24]; p = 0.04) andlate apoptotic and necrotic (HR: 1.10 [95% CI: 0.99–1.23]; p = 0.08) lymphocytes 24-h postirradiationwere found in patients with a bowel bother score decrease greater than 20 pointsmore than 1 year after treatment. Conclusion: Chromatid aberration and apoptosis/necrosisassays appear to be suitable for the prediction of radiation-induced toxicity.
536 _ _ |a 899 - ohne Topic (POF3-899)
|0 G:(DE-HGF)POF3-899
|c POF3-899
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef
650 2 7 |a Medicine
|0 V:(DE-MLZ)SciArea-190
|2 V:(DE-HGF)
|x 0
700 1 _ |a Brzozowska, Kinga
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Kriehuber, Ralf
|0 P:(DE-Juel1)133469
|b 2
|u fzj
700 1 _ |a Eble, Michael J
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Schmitz, Sabine
|0 P:(DE-Juel1)133346
|b 4
|u fzj
773 _ _ |a 10.2217/fon.15.334
|g Vol. 12, no. 5, p. 617 - 624
|0 PERI:(DE-600)2184533-5
|n 5
|p 617 - 624
|t Future oncology
|v 12
|y 2016
|x 1744-8301
909 C O |o oai:juser.fz-juelich.de:808538
|p VDB
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 2
|6 P:(DE-Juel1)133469
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 4
|6 P:(DE-Juel1)133346
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF3-890
|0 G:(DE-HGF)POF3-899
|2 G:(DE-HGF)POF3-800
|v ohne Topic
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b FUTURE ONCOL : 2014
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)S-US-20090406
|k S-US
|l Sicherheit und Strahlenschutz, Umgebungsüberwachung,Strahlenbiologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)S-US-20090406
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21